Nomograms and risk score models for predicting survival in rectal cancer patients with neoadjuvant therapy

Table 2 Clinical data before surgery

Variable	Primary cohort (n = 155)		Validation cohort (n = 65)
	No. of patients	%	No. of patients	%
Preoperative chemotherapy cycle
Median	2.00		3.00
Range	2.00-3.00		2.00-3.00
Surgery a few weeks after radiotherapy
Median	8.00		9.00
Range	7.00-11.00		7.00-15.00
Distance from margin before NT
Median	5.00		5.00
Range	3.00-7.00		3.00-7.00
Distance from margin after NT
Median	5.00		5.00
Range	3.00-7.00		3.00-7.00
Preoperative CEA
Median	2.85		3.35
Range	1.60-4.73		1.52-6.21
cT
2			1	1.5
3	120	77.4	52	80
4	35	22.6	12	18.5
cN
0	54	34.8	21	32.3
1	73	47.1	33	50.8
2	28	18.1	11	16.9
cM
0	146	94.2	62	95.4
1	9	5.8	3	4.6
cTNM
2	52	33.5	21	32.3
3	94	60.6	41	63.1
4	9	5.8	3	4.6
yT
0	22	14.2	8	12.3
1	4	26	1	1.5
2	34	21.9	15	23.1
3	84	54.2	35	53.8
4	11	7.1	6	9.2
yN
0	88	56.8	33	50.8
1	47	30.3	23	35.4
2	19	12.3	9	13.8
3	1	0.6
yM
0	146	94.2	62	95.4
1	9	5.8	3	4.6
ypTNM
0	21	13.5	8	12.3
1	28	18.1	12	18.5
2	39	25.2	15	23.1
3	58	37.4	27	41.5
4	9	5.8	3	4.6
Pathological changes after treatment
1	85	54.8	38	58.5
2	48	31	19	29.2
3	22	14.2	8	12.3
TRG
0	3	1.9	2	3.1
1	27	17.4	14	21.5
2	62	40	26	40.0
3	41	26.5	15	23.1
4	22	14.2	8	12.3
Preoperative simultaneous chemotherapy
Yes	126	81.3	51	78.5
No	29	18.7	14	21.5
Preoperative radiotherapy
Yes	3	1.9	4	6.2
No	152	98.1	61	93.8
Preoperative chemotherapy
Yes	26	16.8	10	15.4
No	129	83.2	55	84.6

CEA: Carcinoembryonic antigen; TRG: Tumor regression grade. Pathological changes after treatment, 1: no-downstaging; 2: downstaging; 3: Polymerase chain reaction.